Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma

Abstract CD204 is a specific marker of tumor‐associated macrophages (TAMs) in glioma. However, the expression levels of CD204 and its involvement in glioma are not fully understood. In this large‐scale study, we assessed the expression and function of CD204 in whole‐grade glioma molecularly and clin...

Full description

Bibliographic Details
Main Authors: Yongliang Yuan, Qitai Zhao, Songfeng Zhao, Penghua Zhang, Haibiao Zhao, Zeyun Li, Yue Du, Xin Tian, Jingli Lu
Format: Article
Language:English
Published: Wiley 2019-07-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.2312
_version_ 1811221285955436544
author Yongliang Yuan
Qitai Zhao
Songfeng Zhao
Penghua Zhang
Haibiao Zhao
Zeyun Li
Yue Du
Xin Tian
Jingli Lu
author_facet Yongliang Yuan
Qitai Zhao
Songfeng Zhao
Penghua Zhang
Haibiao Zhao
Zeyun Li
Yue Du
Xin Tian
Jingli Lu
author_sort Yongliang Yuan
collection DOAJ
description Abstract CD204 is a specific marker of tumor‐associated macrophages (TAMs) in glioma. However, the expression levels of CD204 and its involvement in glioma are not fully understood. In this large‐scale study, we assessed the expression and function of CD204 in whole‐grade glioma molecularly and clinically. In total, 1323 glioma samples, including 301 microarray data and 325 RNA‐seq data from the Chinese Glioma Genome Atlas (CGGA) dataset and 697 RNA‐seq data from The Cancer Genome Atlas (TCGA) dataset, were utilized. The statistical analysis and graphical work were mainly performed using the R software. Univariate and multivariate Cox analysis demonstrated that CD204 was an independent prognosticator in glioma patients. CD204 expression was positively correlated with the grade of malignancy. CD204 was consistently upregulated in wild‐type isocitrate dehydrogenase glioma and highly expressed in mesenchymal glioblastoma. Gene ontology of CD204‐related genes showed that CD204 was most enriched in inflammatory response and immune response. It was associated with the stromal and immune populations, especially the monocytic lineage, fibroblasts, and T cells. Circos plots revealed that CD204 was closely associated with many immune checkpoint regulators, especially TIM‐3. CD204 expression is consistent with the malignant phenotype of glioma and independently predicts poor outcomes in glioma patients. Additionally, CD204+ TAMs, collaborating with other checkpoint members, may contribute to the dysfunction of T cells. These findings suggest that CD204 may be a promising target for glioma immunotherapy.
first_indexed 2024-04-12T07:56:44Z
format Article
id doaj.art-ac43616f94cc44c3958a14ccac1c2dac
institution Directory Open Access Journal
issn 2045-7634
language English
last_indexed 2024-04-12T07:56:44Z
publishDate 2019-07-01
publisher Wiley
record_format Article
series Cancer Medicine
spelling doaj.art-ac43616f94cc44c3958a14ccac1c2dac2022-12-22T03:41:27ZengWileyCancer Medicine2045-76342019-07-01883811382110.1002/cam4.2312Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse gliomaYongliang Yuan0Qitai Zhao1Songfeng Zhao2Penghua Zhang3Haibiao Zhao4Zeyun Li5Yue Du6Xin Tian7Jingli Lu8Department of Pharmacy The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaBiotherapy Center The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Pharmacy The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaImaging Department The Third Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Neurosurgery The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Pharmacy The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Pharmacy The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Pharmacy The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Pharmacy The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaAbstract CD204 is a specific marker of tumor‐associated macrophages (TAMs) in glioma. However, the expression levels of CD204 and its involvement in glioma are not fully understood. In this large‐scale study, we assessed the expression and function of CD204 in whole‐grade glioma molecularly and clinically. In total, 1323 glioma samples, including 301 microarray data and 325 RNA‐seq data from the Chinese Glioma Genome Atlas (CGGA) dataset and 697 RNA‐seq data from The Cancer Genome Atlas (TCGA) dataset, were utilized. The statistical analysis and graphical work were mainly performed using the R software. Univariate and multivariate Cox analysis demonstrated that CD204 was an independent prognosticator in glioma patients. CD204 expression was positively correlated with the grade of malignancy. CD204 was consistently upregulated in wild‐type isocitrate dehydrogenase glioma and highly expressed in mesenchymal glioblastoma. Gene ontology of CD204‐related genes showed that CD204 was most enriched in inflammatory response and immune response. It was associated with the stromal and immune populations, especially the monocytic lineage, fibroblasts, and T cells. Circos plots revealed that CD204 was closely associated with many immune checkpoint regulators, especially TIM‐3. CD204 expression is consistent with the malignant phenotype of glioma and independently predicts poor outcomes in glioma patients. Additionally, CD204+ TAMs, collaborating with other checkpoint members, may contribute to the dysfunction of T cells. These findings suggest that CD204 may be a promising target for glioma immunotherapy.https://doi.org/10.1002/cam4.2312biomarkerCD204gliomaimmune checkpointsprognosis
spellingShingle Yongliang Yuan
Qitai Zhao
Songfeng Zhao
Penghua Zhang
Haibiao Zhao
Zeyun Li
Yue Du
Xin Tian
Jingli Lu
Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma
Cancer Medicine
biomarker
CD204
glioma
immune checkpoints
prognosis
title Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma
title_full Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma
title_fullStr Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma
title_full_unstemmed Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma
title_short Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma
title_sort characterization of transcriptome profile and clinical features of a novel immunotherapy target cd204 in diffuse glioma
topic biomarker
CD204
glioma
immune checkpoints
prognosis
url https://doi.org/10.1002/cam4.2312
work_keys_str_mv AT yongliangyuan characterizationoftranscriptomeprofileandclinicalfeaturesofanovelimmunotherapytargetcd204indiffuseglioma
AT qitaizhao characterizationoftranscriptomeprofileandclinicalfeaturesofanovelimmunotherapytargetcd204indiffuseglioma
AT songfengzhao characterizationoftranscriptomeprofileandclinicalfeaturesofanovelimmunotherapytargetcd204indiffuseglioma
AT penghuazhang characterizationoftranscriptomeprofileandclinicalfeaturesofanovelimmunotherapytargetcd204indiffuseglioma
AT haibiaozhao characterizationoftranscriptomeprofileandclinicalfeaturesofanovelimmunotherapytargetcd204indiffuseglioma
AT zeyunli characterizationoftranscriptomeprofileandclinicalfeaturesofanovelimmunotherapytargetcd204indiffuseglioma
AT yuedu characterizationoftranscriptomeprofileandclinicalfeaturesofanovelimmunotherapytargetcd204indiffuseglioma
AT xintian characterizationoftranscriptomeprofileandclinicalfeaturesofanovelimmunotherapytargetcd204indiffuseglioma
AT jinglilu characterizationoftranscriptomeprofileandclinicalfeaturesofanovelimmunotherapytargetcd204indiffuseglioma